Journal
NANOSCALE
Volume 13, Issue 6, Pages 3500-3511Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/d0nr07145e
Keywords
-
Categories
Funding
- Health Institute Carlos III (ISCIII) [DTS18/00121]
- Junta de Andalucia-FEDER, Ministry of Economy, Knowledge, Companies and University (University of Granada) [B-FQM-475-UGR18, PT18-TP-1490, AT17_6096- OTRI]
- Spanish State Research Agency [RED2018-102469-T]
- Fundacion Benefica Anticancer San Francisco Javier y Santa Candida
- Spanish Ministry of Economy and Competitiveness [PTQ-16- 08597]
- Spanish Ministry of Education [FPU 16/02061]
Ask authors/readers for more resources
This manuscript reports the development of a versatile, robust, and stable targeting nanocarrier for active delivery, which can efficiently discriminate between cells based on cell surface receptor expressions. The nanocarrier has been successfully demonstrated for efficient delivery using two different cell surface receptors, providing potential applications in cancer treatment and personalized medicine.
In this manuscript, we report the development of a versatile, robust, and stable targeting nanocarrier for active delivery. This nanocarrier is based on bifunctionalized polymeric nanoparticles conjugated to a monoclonal antibody that allows for active targeting of either (i) a fluorophore for tracking or (ii) a drug for monitoring specific cell responses. This nanodevice can efficiently discriminate between cells in coculture based on the expression levels of cell surface receptors. As a proof of concept, we have demonstrated efficient delivery using a broadly established cell surface receptor as the target, the epidermal growth factor receptor (EGFR), which is overexpressed in several types of cancers. Additionally, a second validation of this nanodevice was successfully carried out using another cell surface receptor as the target, the cluster of differentiation 147 (CD147). Our results suggest that this versatile nanocarrier can be expanded to other cell receptors and bioactive cargoes, offering remarkable discrimination efficiency between cells with different expression levels of a specific marker. This work supports the ability of nanoplatforms to boost and improve the progress towards personalized medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available